We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.38B
AUM Growth
-$480M
Cap. Flow
+$130M
Cap. Flow %
2.42%
Top 10 Hldgs %
41.73%
Holding
224
New
23
Increased
133
Reduced
36
Closed
13

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$23.8M
2
GKOS icon
Glaukos
GKOS
+$20.8M
3
ARVN icon
Arvinas
ARVN
+$19.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
5
PACB icon
Pacific Biosciences
PACB
+$13.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$72.6M
2
GILD icon
Gilead Sciences
GILD
+$33.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$23.2M
4
TDOC icon
Teladoc Health
TDOC
+$19.5M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.28%
2 Industrials 0.53%
3 Technology 0.51%
4 Financials 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVS icon
101
CVS Health
CVS
$137B
$6.67M 0.12%
105,688
+46,362
+78% +$2.75M
VCRA
102
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$6.14M 0.11%
249,173
+55,539
+29% +$1.44M
GH icon
103
Guardant Health
GH
$20.7B
$6.05M 0.11%
94,761
-25,087
-21% -$2.21M
QTNT
104
DELISTED
Quotient Limited Ordinary Shares
QTNT
$5.81M 0.11%
18,697
+361
+2% +$139K
VTRS icon
105
Viatris
VTRS
$20.1B
$5.8M 0.11%
+293,200
New +$5.75M
INGN icon
106
Inogen
INGN
$178M
$5.43M 0.1%
113,323
+16,480
+17% +$860K
PHR icon
107
Phreesia
PHR
$662M
$5.35M 0.1%
+220,690
New +$5.82M
AGN
108
DELISTED
Allergan plc
AGN
$5.18M 0.1%
30,800
-1,300
-4% -$212K
HCAT icon
109
Health Catalyst
HCAT
$166M
$5.07M 0.09%
+160,216
New +$6.31M
TXG icon
110
10x Genomics
TXG
$5.55B
$5.04M 0.09%
+100,000
New +$5.53M
SDC
111
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$4.86M 0.09%
+350,000
New +$5.84M
CDTX
112
DELISTED
Cidara Therapeutics
CDTX
$4.58M 0.09%
114,764
– –
MTLS
113
Materialise
MTLS
$379M
$4.45M 0.08%
240,770
– –
SILK
114
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$4.29M 0.08%
131,954
+5,144
+4% +$205K
CHRS icon
115
Coherus Oncology
CHRS
$216M
$4.08M 0.08%
201,435
+34,800
+21% +$695K
HSIC icon
116
Henry Schein
HSIC
$10B
$4.04M 0.08%
63,575
+5,658
+10% +$366K
KZR
117
DELISTED
Kezar Life Sciences
KZR
$4.04M 0.08%
123,052
– –
PEN icon
118
Penumbra
PEN
$12.5B
$3.37M 0.06%
25,048
-132
-0.5% -$20.4K
SYNH
119
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$3.3M 0.06%
62,000
– –
ACAD icon
120
Acadia Pharmaceuticals
ACAD
$4.38B
$3.25M 0.06%
90,400
-13,400
-13% -$406K
SWAV
121
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$3.03M 0.06%
101,358
+3,811
+4% +$162K
AVTR icon
122
Avantor
AVTR
$7.56B
$2.9M 0.05%
196,951
+9,720
+5% +$165K
PTCT icon
123
PTC Therapeutics
PTCT
$6.52B
$2.75M 0.05%
81,200
-2,300
-3% -$100K
STIM icon
124
Neuronetics
STIM
$113M
$2.71M 0.05%
325,961
+1,182
+0.4% +$12.9K
KURA icon
125
Kura Oncology
KURA
$964M
$2.52M 0.05%
166,300
+21,100
+15% +$376K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2019 Portfolio in Review

As of Q3 2019, Bellevue Group held 224 positions worth $5.38B, down 8.2% from $5.86B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group's Q3 2019 filing shows 23 new, 133 increased, 36 reduced and 13 closed positions. Its largest new stake was Arvinas: 806,403 shares worth $17.4M. The largest sale was Celgene Corp, an estimated $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2019 buy was Arvinas: 806,403 shares worth $17.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2019, an estimated $23.8M increase.
  • Bellevue Group's biggest Q3 2019 reduction was Celgene Corp, cutting an estimated $72.6M.
  • Bellevue Group fully exited Avedro, Inc Common Stock in Q3 2019, selling an estimated $15.8M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.38B portfolio in Q3 2019.
  • Bellevue Group opened 23 new positions and closed 13 in Q3 2019.
  • Bellevue Group's portfolio value fell 8.2% quarter-over-quarter to $5.38B.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.